The Medicines Evaluation Board (MEB) assesses and monitors the efficacy, risks and quality of human and veterinary medicines, and the safety of novel foods for human consumption.
The MEB is an independent administrative body residing under the Government of the Netherlands. The MEB independently decides about the authorisation and monitoring of human medicinal products.
Assessment criteria for combination packages policy established
The Medicines Evaluation Board (MEB) has described the terms and conditions which are to be used to assess applications for...
MEB Annual Report: a leading player in Europe again in 2016
The Medicines Evaluation Board (MEB) was one of the leading players in Europe in the field of medicine assessment and...
New legal EudraVigilance obligations as of 22 November 2017
As of 22 November 2017 new obligations in respect of signal management and reporting of suspected adverse reactions (ADRs) will...
Eric Boersma sworn in as new MEB Member
Mr Prof H. (Eric) Boersma was sworn in as a new member of the Medicines Evaluation Board (MEB) on 1 June 2017.